Recent approval of Biogen's Aduhelm and a new cancer immunotherapy under the spotlight
The dust has started to settle after a busy and at times controversial few weeks in the biopharma market.
A notable development at the recent ASCO annual meeting was presentation of clinical data for Bristol Myers Squibb's relatlimab, a potential first-in-class LAG-3 inhibitor. Investment in new checkpoint inhibitor targets continues apace, as demonstrated by yesterday's announcement that GlaxoSmithKline will pay $625 million upfront to in-license an experimental anti-TIGIT drug from iTeos Therapeutics.
Later today (June 15 at 10am ET / 3pm GMT), executive editor Michael Flanagan will host a live conversation with Dr. Michael Atkins, deputy director of the Georgetown-Lombardi Comprehensive Cancer Center and professor of medical oncology at Georgetown University Medical Center, to discuss expectations for relatlimab in melanoma and the broader outlook for LAG-3 inhibitors.
Register to attend that event here.
On Wednesday (June 16 at 10am ET / 3pm GMT), Michael will also join me to discuss the recent FDA approval of Biogen and Eisai's Aduhelm (aducanumab) as a first potential disease modifying treatment for Alzheimer's disease.
Attendees will also get exclusive access to results from our new survey of 50 US-based neurologists assessing how Aduhelm will be used once it is launched in the next couple of weeks.
Sign up for the Aduhelm discussion here.
Have a good week.
Simon King – Executive Editor, Insight, Analysis and Views
To read more ViewPoints articles, click here.